• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Bionano Genomics Inc.

    4/28/25 4:17:17 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BNGO alert in real time by email
    DEFA14A 1 ny20044950x3_defa14a.htm DEFA 14A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant  ☐
    Check the appropriate box:
    ☐
    ​ ​
    Preliminary Proxy Statement
     ☐
    ​ ​
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
     ☐
    ​ ​
    Definitive Proxy Statement
    ☒
    ​ ​
    Definitive Additional Materials
     ☐
    ​ ​
    Soliciting Material Pursuant to § 240.14a-12
    Bionano Genomics, Inc.
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    ☒
    ​ ​
    No fee required.
     ☐
    ​ ​
    Fee paid previously with preliminary materials.
     ☐
    ​ ​
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



    Get the next $BNGO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNGO

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    More analyst ratings

    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the second quarter ended June 30, 2025. "We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter. These routine users are increasingly leveraging our OGM systems and software and we believe the recent upgrades to our software and compute platforms will drive further utilization. I'm very proud of our team for driving gross margin above 50% this quarter, which combined with our continued efforts to reduce costs, gives

    8/14/25 4:01:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL

    SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and colleagues from multiple French pediatric hematology centers showing how optical genome mapping (OGM) can be used to detect oncogenic structural variants (SVs) in clinical research of infant and toddler T-cell acute lymphoblastic leukemia (T-ALL). The publication shows that OGM can reveal distinct genetic drivers and prognostic subgroups that conventional cytogenetics failed to identify in a retrospective, national cohort of 27 T-ALL cases of infants and toddlers (<3 years) as part

    8/7/25 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference

    SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. Conference & Webcast Details Date:August 13, 2025Time:3:00 p.m. to 3:25 p.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the Bionano website at https://ir.bionano.com/ for at least 30 days. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians t

    8/6/25 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    SEC Filings

    View All

    SEC Form 10-Q filed by Bionano Genomics Inc.

    10-Q - Bionano Genomics, Inc. (0001411690) (Filer)

    8/14/25 4:13:27 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bionano Genomics, Inc. (0001411690) (Filer)

    8/14/25 4:04:18 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Bionano Genomics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K/A - Bionano Genomics, Inc. (0001411690) (Filer)

    6/18/25 5:15:40 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Twomey Christopher J

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    6/12/25 4:51:11 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Vuori Kristiina Md

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    6/12/25 4:50:58 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Linney Yvonne

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    6/12/25 4:50:47 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bionano Genomics downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

    11/15/24 7:40:01 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics downgraded by BTIG Research

    BTIG Research downgraded Bionano Genomics from Buy to Neutral

    9/10/24 7:37:53 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on Bionano Genomics with a new price target

    Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

    1/5/23 7:29:54 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Leadership Updates

    Live Leadership Updates

    View All

    LeddarTech Appoints Chris Stewart as Chief Financial Officer

    QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

    11/15/23 12:07:00 AM ET
    $BNGO
    $PRSR
    $TSLA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Blank Checks
    Finance

    Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

    SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

    8/14/23 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

    SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l

    11/10/22 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Financials

    Live finance-specific insights

    View All

    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the second quarter ended June 30, 2025. "We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter. These routine users are increasingly leveraging our OGM systems and software and we believe the recent upgrades to our software and compute platforms will drive further utilization. I'm very proud of our team for driving gross margin above 50% this quarter, which combined with our continued efforts to reduce costs, gives

    8/14/25 4:01:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025

    SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, August 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, August 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/tnombut6/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h

    7/31/25 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

    SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

    5/7/25 4:01:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    2/13/24 5:00:51 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    7/7/23 4:35:55 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    1/30/23 4:03:23 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials